Activity of Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia with Chromosome 17 Deletion


Activity of Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia with Chromosome 17 Deletion
Slides from a presentation at ICML 2013 and transcribed comments from recent interviews with Jonathan W Friedberg, MD, MMSc (7/18/13) and Brad S Kahl, MD (9/10/13)

Wiestner A et al. Single agent ibrutinib (PCI-32765) is highly effective in chronic lymphocytic leukaemia patients with 17P deletion. Proc ICML 2013;Abstract 008.

Dr Friedberg is Samuel Durand Professor of Medicine and Director of the Wilmot Cancer Center at the University of Rochester in Rochester, New York.

Dr Kahl is Skoronski Chair of Lymphoma Research and Associate Professor at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical Research at UW Carbone Cancer Center in Madison, Wisconsin.